I he by certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU578405130US, in an envelope addressed to: Box Non-Fee hendment, Commissioner for Patents, Washington, DC 20231, on the date shown RADEN

Docket No.: HO-P01938US0

Examiner: Saunders, David

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Morten Soegaard, et al.

Application No.: 09/463,470

Filed: January 21, 2000

For: CYTOLYSIS OF TARGET CELLS BY

SUPERANTIGEN CONJUGATES INDUCING

T-CELL ACTIVATION

TECH CENTER 1600/2000 Group Art Unit: 1644

AMENDMENT

Box Non-Fee Amendment

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Office Action dated July 11, 2002 (Paper No. 14), please amend the above-identified U.S. patent application as follows:

In the Specification

Please substitute the following references indicated on identified page and line numbers.

Page 60, line 2

*Bamborough et al (1994) Structure 2:839-51.

Page 60, lines 21-22

*Belfrage et al (1997b) Prevention of superantigen induced tolerance in vivo by IL-2 treatment. Cancer Immunol. Immunother. 44:77-82.

Page 60, line 23

25215941.1

BI

EU578405130US